bioAffinity Technologies (BIAF) Competitors

Veritone (NASDAQ:VERI) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Which has preferable earnings and valuation, VERI or BIAF?

bioAffinity Technologies has lower revenue, but higher earnings than Veritone. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Veritone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veritone	$127.56M	0.88	-$58.62M	-$2.20	-1.35
bioAffinity Technologies	$2.53M	12.49	-$7.94M	-$0.93	-2.91

Does the media refer more to VERI or BIAF?

In the previous week, Veritone and Veritone both had 5 articles in the media. bioAffinity Technologies' average media sentiment score of 0.82 beat Veritone's score of 0.37 indicating that Veritone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veritone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in VERI or BIAF?

39.2% of Veritone shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 26.6% of Veritone shares are owned by company insiders. Comparatively, 36.4% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more volatility and risk, VERI or BIAF?

Veritone has a beta of 3.33, meaning that its stock price is 233% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500.

Does the MarketBeat Community believe in VERI or BIAF?

Veritone received 305 more outperform votes than bioAffinity Technologies when rated by MarketBeat users. However, 100.00% of users gave bioAffinity Technologies an outperform vote while only 61.20% of users gave Veritone an outperform vote.

Company	Underperform	Outperform
Veritone	Outperform Votes 306 61.20%	Underperform Votes 194 38.80%
bioAffinity Technologies	Outperform Votes 1 100.00%	Underperform Votes No Votes

Do analysts recommend VERI or BIAF?

Veritone presently has a consensus price target of $2.25, indicating a potential downside of 23.99%. bioAffinity Technologies has a consensus price target of $6.00, indicating a potential upside of 121.40%. Given Veritone's stronger consensus rating and higher possible upside, analysts plainly believe bioAffinity Technologies is more favorable than Veritone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veritone	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
bioAffinity Technologies	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is VERI or BIAF more profitable?

Veritone has a net margin of -44.39% compared to Veritone's net margin of -171.43%. Veritone's return on equity of -134.34% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veritone	-44.39%	-154.87%	-11.82%
bioAffinity Technologies	-171.43%	-134.34%	-95.83%

Summary

bioAffinity Technologies beats Veritone on 9 of the 17 factors compared between the two stocks.